ALYSSA HOLLINGSWORTH: Open Payments
NPI 1962085662 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,083 in 205 payments from 12 companies in 2025. Trend: 2023 $3,856 · 2024 $3,036 · 2025 $3,083
Food & beverage: $2,983Education: $100
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 37 | $597 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $430 |
| E.R. Squibb & Sons, L.L.C. | 37 | $425 |
| Alkermes, Inc. | 17 | $312 |
| Otsuka America Pharmaceutical, Inc. | 16 | $308 |
| ABBVIE INC. | 31 | $265 |
| Vanda Pharmaceuticals Inc. | 14 | $261 |
| Lundbeck LLC | 15 | $184 |
| Neurocrine BioSciences, Inc. | 8 | $169 |
| Janssen Pharmaceuticals, Inc | 4 | $80 |
Products named: CAPLYTA, COBENFY, AUSTEDO XR, REXULTI, ARISTADA, VRAYLAR, FANAPT, INGREZZA.
Industry payments across AL — which companies pay providers there.
